Longboard Pharmaceuticals Statistics
Total Valuation
LILAK has a market cap or net worth of $1.58 billion. The enterprise value is $9.84 billion.
Important Dates
The last earnings date was Thursday, August 7, 2025, before market open.
| Earnings Date | Aug 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
LILAK has 158.50 million shares outstanding. The number of shares has decreased by -0.86% in one year.
| Current Share Class | 158.50M |
| Shares Outstanding | 158.50M |
| Shares Change (YoY) | -0.86% |
| Shares Change (QoQ) | +1.10% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 163.54M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 13.31 |
| PS Ratio | 0.36 |
| Forward PS | n/a |
| PB Ratio | 1.41 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 7.34 |
| P/OCF Ratio | 2.14 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 9.37, with an EV/FCF ratio of 45.60.
| EV / Earnings | n/a |
| EV / Sales | 2.23 |
| EV / EBITDA | 9.37 |
| EV / EBIT | 81.89 |
| EV / FCF | 45.60 |
Financial Position
The company has a current ratio of 1.08, with a Debt / Equity ratio of 7.35.
| Current Ratio | 1.08 |
| Quick Ratio | 0.76 |
| Debt / Equity | 7.35 |
| Debt / EBITDA | 6.86 |
| Debt / FCF | 38.26 |
| Interest Coverage | 0.19 |
Financial Efficiency
Return on equity (ROE) is -68.26% and return on invested capital (ROIC) is 0.74%.
| Return on Equity (ROE) | -68.26% |
| Return on Assets (ROA) | 0.60% |
| Return on Invested Capital (ROIC) | 0.74% |
| Return on Capital Employed (ROCE) | 1.19% |
| Revenue Per Employee | $440,970 |
| Profits Per Employee | -$117,350 |
| Employee Count | 10,000 |
| Asset Turnover | 0.35 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -119.90M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -21.36% in the last 52 weeks. The beta is 0.98, so LILAK's price volatility has been similar to the market average.
| Beta (5Y) | 0.98 |
| 52-Week Price Change | -21.36% |
| 50-Day Moving Average | 6.18 |
| 200-Day Moving Average | 6.52 |
| Relative Strength Index (RSI) | 82.21 |
| Average Volume (20 Days) | 1,732,891 |
Short Selling Information
The latest short interest is 4.39 million, so 2.77% of the outstanding shares have been sold short.
| Short Interest | 4.39M |
| Short Previous Month | 4.21M |
| Short % of Shares Out | 2.77% |
| Short % of Float | 2.69% |
| Short Ratio (days to cover) | 3.27 |
Income Statement
In the last 12 months, LILAK had revenue of $4.41 billion and -$1.17 billion in losses. Loss per share was -$5.88.
| Revenue | 4.41B |
| Gross Profit | 3.44B |
| Operating Income | 120.10M |
| Pretax Income | 13.20M |
| Net Income | -1.17B |
| EBITDA | 1.05B |
| EBIT | 120.10M |
| Loss Per Share | -$5.88 |
Full Income StatementBalance Sheet
The company has $514.40 million in cash and $8.25 billion in debt, giving a net cash position of -$7.74 billion or -$48.82 per share.
| Cash & Cash Equivalents | 514.40M |
| Total Debt | 8.25B |
| Net Cash | -7.74B |
| Net Cash Per Share | -$48.82 |
| Equity (Book Value) | 1.12B |
| Book Value Per Share | 3.04 |
| Working Capital | 143.60M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $741.90 million and capital expenditures -$526.20 million, giving a free cash flow of $215.70 million.
| Operating Cash Flow | 741.90M |
| Capital Expenditures | -526.20M |
| Free Cash Flow | 215.70M |
| FCF Per Share | $1.36 |
Full Cash Flow StatementMargins
Gross margin is 78.03%, with operating and profit margins of 2.72% and -26.61%.
| Gross Margin | 78.03% |
| Operating Margin | 2.72% |
| Pretax Margin | -28.38% |
| Profit Margin | -26.61% |
| EBITDA Margin | 23.82% |
| EBIT Margin | 2.72% |
| FCF Margin | 4.89% |
Dividends & Yields
LILAK does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.86% |
| Shareholder Yield | 0.86% |
| Earnings Yield | -74.08% |
| FCF Yield | 13.62% |
Dividend DetailsAnalyst Forecast
The average price target for LILAK is $10.27, which is 28.54% higher than the current price. The consensus rating is "Buy".
| Price Target | $10.27 |
| Price Target Difference | 28.54% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | 3.21% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 5 |
